SYNOVIAL SARCOMA

This early-phase study tests a new treatment for children and young adults (up to age 26) with solid tumors that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein c…

This study tests a new treatment for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells, called T cells, which are genetically modified in a lab to better recognize and attack cancer cells. The main goa…

This early-phase study tests a personalized cell therapy for children and young adults (ages 1–30) whose solid tumors have come back or not responded to standard treatment. Researchers take a patient's own immune T cells, modify them to recognize and attack cancer cells that carr…

This early-stage study tests whether adding an experimental drug (BO-112) to an immunotherapy (nivolumab) before surgery is safe for people with soft tissue sarcoma that can be removed. The goal is to see if this combination can boost the immune system to better attack the cancer…

This study tests whether adding the drug pazopanib to standard radiation or chemoradiation helps shrink soft tissue sarcomas before surgery. About 140 patients with newly diagnosed, removable tumors took part. The goal is to see if the combination is safe and improves tumor respo…

This study tests a new treatment called ADP-A2M4 for people with advanced synovial sarcoma or myxoid liposarcoma that has spread or cannot be removed by surgery. The treatment uses a patient's own immune cells that are modified in a lab to better recognize and attack cancer cells…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma). The therapy takes a patient's own immune cells and genetically equips them to recognize and attack tumors that …